Literature DB >> 18215601

Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study.

Gregory M Marcus1, Mary A Whooley, David V Glidden, Ludmila Pawlikowska, Jonathan G Zaroff, Jeffrey E Olgin.   

Abstract

BACKGROUND: Previous studies suggest that markers of inflammation are elevated in patients with atrial fibrillation (AF). However, because inflammation has been implicated in contributing to risk of both AF and coronary artery disease (CAD), which are often present in the same populations, it is important to control for confounding by the presence of CAD. We therefore examined several biomarkers of inflammation and ultimately genotyped IL-6 polymorphisms in patients with AF in a cohort of subjects with known CAD.
METHODS: We performed a cross-sectional analysis of 971 participants in the Heart and Soul Study, 46 of whom had AF. Interleukin-6, C-reactive protein, tumor necrosis factor-alpha, CD-40 ligand, monocyte chemoattractant protein-1, and fibrinogen levels were measured.
RESULTS: In both unadjusted and adjusted analyses, IL-6 was the only biomarker significantly associated with AF (median IL-6 3.76 and 2.52 pg/mL in those with and without AF, respectively, P = .0005; adjusted odds ratio 1.77, P = .032). The IL-6-174CC genotype was significantly associated with the presence of AF in the adjusted analysis (odds ratio 2.34, P = .04) and with higher IL-6 levels (P = .002).
CONCLUSIONS: In this cohort of subjects with CAD, AF was significantly associated with elevated IL-6 levels and the IL-6-174CC genotype. No associations were found with other biomarkers, including C-reactive protein. This suggests that IL-6 is a uniquely important mediator in the pathophysiology of AF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18215601      PMCID: PMC2247366          DOI: 10.1016/j.ahj.2007.09.006

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  32 in total

1.  C-Reactive protein in lone atrial fibrillation.

Authors:  Patrick T Ellinor; Adrian Low; Kristen K Patton; Marisa A Shea; Calum A MacRae
Journal:  Am J Cardiol       Date:  2006-03-20       Impact factor: 2.778

2.  CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study.

Authors:  David H McDermott; Qiong Yang; Sekar Kathiresan; L Adrienne Cupples; Joseph M Massaro; John F Keaney; Martin G Larson; Ramachandran S Vasan; Joel N Hirschhorn; Christopher J O'Donnell; Philip M Murphy; Emelia J Benjamin
Journal:  Circulation       Date:  2005-08-23       Impact factor: 29.690

3.  Adrenoceptor polymorphisms and the risk of cardiac injury and dysfunction after subarachnoid hemorrhage.

Authors:  Jonathan G Zaroff; Ludmila Pawlikowska; Jacob C Miss; Sirisha Yarlagadda; Connie Ha; Achal Achrol; Pui-Yan Kwok; Charles E McCulloch; Michael T Lawton; Nerissa Ko; Wade Smith; William L Young
Journal:  Stroke       Date:  2006-05-25       Impact factor: 7.914

4.  Interleukin 6 G-174C polymorphism influences outcome following coronary revascularization surgery.

Authors:  Mohamad N Bittar; John A Carey; James Barnard; James E Fildes; Vera Pravica; Nizar Yonan; Ian V Hutchinson
Journal:  Heart Surg Forum       Date:  2005       Impact factor: 0.676

5.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.

Authors:  D Li; S Fareh; T K Leung; S Nattel
Journal:  Circulation       Date:  1999-07-06       Impact factor: 29.690

6.  Histological substrate of atrial biopsies in patients with lone atrial fibrillation.

Authors:  A Frustaci; C Chimenti; F Bellocci; E Morgante; M A Russo; A Maseri
Journal:  Circulation       Date:  1997-08-19       Impact factor: 29.690

7.  Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy.

Authors:  Stefan Göser; Renate Ottl; Alexander Brodner; Thomas J Dengler; Jan Torzewski; Kensuke Egashira; Noel R Rose; Hugo A Katus; Ziya Kaya
Journal:  Circulation       Date:  2005-11-29       Impact factor: 29.690

8.  Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation.

Authors:  Stavroula N Psychari; Thomas S Apostolou; Loukas Sinos; Eftihia Hamodraka; George Liakos; Dimitrios Th Kremastinos
Journal:  Am J Cardiol       Date:  2005-03-15       Impact factor: 2.778

9.  C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study.

Authors:  Karolina Tuomisto; Pekka Jousilahti; Jouko Sundvall; Pia Pajunen; Veikko Salomaa
Journal:  Thromb Haemost       Date:  2006-03       Impact factor: 5.249

10.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.

Authors:  E J Benjamin; D Levy; S M Vaziri; R B D'Agostino; A J Belanger; P A Wolf
Journal:  JAMA       Date:  1994-03-16       Impact factor: 56.272

View more
  62 in total

Review 1.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

Review 2.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 3.  Inflammation and the pathogenesis of atrial fibrillation.

Authors:  Yu-Feng Hu; Yi-Jen Chen; Yenn-Jiang Lin; Shih-Ann Chen
Journal:  Nat Rev Cardiol       Date:  2015-01-27       Impact factor: 32.419

Review 4.  Role of inflammation in atrial fibrillation pathophysiology and management.

Authors:  Masahide Harada; David R Van Wagoner; Stanley Nattel
Journal:  Circ J       Date:  2015-02-16       Impact factor: 2.993

5.  Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial.

Authors:  C N Pellegrini; E Vittinghoff; F Lin; S B Hulley; G M Marcus
Journal:  Heart       Date:  2009-01-28       Impact factor: 5.994

6.  Psychological risk factors and the metabolic syndrome in patients with coronary heart disease: findings from the Heart and Soul Study.

Authors:  Beth E Cohen; Praveen Panguluri; Beeya Na; Mary A Whooley
Journal:  Psychiatry Res       Date:  2009-12-06       Impact factor: 3.222

7.  Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1.

Authors:  Dolkun Rahmutula; Gregory M Marcus; Emily E Wilson; Chun-Hua Ding; Yuanyuan Xiao; Agnes C Paquet; Rebecca Barbeau; Andrea J Barczak; David J Erle; Jeffrey E Olgin
Journal:  Cardiovasc Res       Date:  2013-04-23       Impact factor: 10.787

Review 8.  Pleiotropic effects of statins in atrial fibrillation patients: the evidence.

Authors:  Hadi Ar Hadi; Wael Al Mahmeed; Jassim Al Suwaidi; Samer Ellahham
Journal:  Vasc Health Risk Manag       Date:  2009-06-29

Review 9.  Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance.

Authors:  Irene Savelieva; Antonios Kourliouros; John Camm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-25       Impact factor: 3.000

10.  Relation of multiple inflammatory biomarkers to incident atrial fibrillation.

Authors:  Renate B Schnabel; Martin G Larson; Jennifer F Yamamoto; Sekar Kathiresan; Jian Rong; Daniel Levy; John F Keaney; Thomas J Wang; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Am J Cardiol       Date:  2009-05-04       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.